Teza Capital Management LLC Acquires New Position in Iqvia Holdings Inc (NYSE:IQV)

Teza Capital Management LLC acquired a new position in shares of Iqvia Holdings Inc (NYSE:IQV) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,807 shares of the medical research company’s stock, valued at approximately $1,555,000. Iqvia makes up approximately 0.8% of Teza Capital Management LLC’s investment portfolio, making the stock its 21st largest position.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of Iqvia by 7.0% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,251 shares of the medical research company’s stock worth $1,331,000 after purchasing an additional 608 shares during the period. Advisory Services Network LLC boosted its position in Iqvia by 37.4% during the fourth quarter. Advisory Services Network LLC now owns 5,825 shares of the medical research company’s stock valued at $677,000 after buying an additional 1,587 shares during the period. MUFG Securities EMEA plc boosted its position in Iqvia by 2,517.2% during the fourth quarter. MUFG Securities EMEA plc now owns 115,000 shares of the medical research company’s stock valued at $13,360,000 after buying an additional 110,606 shares during the period. Globeflex Capital L P boosted its position in Iqvia by 96.6% during the first quarter. Globeflex Capital L P now owns 10,784 shares of the medical research company’s stock valued at $1,551,000 after buying an additional 5,299 shares during the period. Finally, Meridian Wealth Advisors LLC boosted its position in Iqvia by 13.0% during the first quarter. Meridian Wealth Advisors LLC now owns 4,197 shares of the medical research company’s stock valued at $604,000 after buying an additional 482 shares during the period. 89.69% of the stock is owned by hedge funds and other institutional investors.

Iqvia stock opened at $160.90 on Friday. The firm has a 50-day moving average of $140.81. Iqvia Holdings Inc has a 1 year low of $98.17 and a 1 year high of $160.91. The stock has a market cap of $30.70 billion, a PE ratio of 31.43, a price-to-earnings-growth ratio of 1.89 and a beta of 0.77. The company has a debt-to-equity ratio of 1.69, a quick ratio of 1.14 and a current ratio of 1.14.

Iqvia (NYSE:IQV) last announced its quarterly earnings results on Wednesday, May 1st. The medical research company reported $1.53 earnings per share for the quarter, topping the consensus estimate of $1.41 by $0.12. Iqvia had a net margin of 2.35% and a return on equity of 15.08%. The firm had revenue of $2.68 billion during the quarter, compared to analysts’ expectations of $2.67 billion. During the same quarter in the prior year, the company earned $1.34 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. On average, research analysts predict that Iqvia Holdings Inc will post 5.89 earnings per share for the current year.

IQV has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Iqvia from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Leerink Swann began coverage on shares of Iqvia in a research note on Tuesday, May 28th. They set an “outperform” rating and a $136.38 target price for the company. Stifel Nicolaus raised their price target on shares of Iqvia from $167.00 to $178.00 and gave the company a “buy” rating in a research report on Wednesday, June 19th. SunTrust Banks raised their price target on shares of Iqvia from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Credit Suisse Group lifted their target price on shares of Iqvia from $159.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 19th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $155.49.

In other news, insider Kevin C. Knightly sold 46,080 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $138.06, for a total value of $6,361,804.80. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Ari Bousbib sold 96,000 shares of the firm’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $150.00, for a total transaction of $14,400,000.00. The disclosure for this sale can be found here. Insiders sold 143,273 shares of company stock worth $20,934,730 in the last quarter. Company insiders own 6.00% of the company’s stock.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: Technical Analysis

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.